Dr John Kevin Schweninger, DO | |
34 Hughes Rd, Suite B, Madison, AL 35758-3000 | |
(256) 319-0115 | |
Not Available |
Full Name | Dr John Kevin Schweninger |
---|---|
Gender | Male |
Speciality | Ophthalmology |
Location | 34 Hughes Rd, Madison, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487640934 | NPI | - | NPPES |
2465853 | Other | FL | AETNA |
80060 | Other | FL | BLUE CROSS/BLUE SHIELD |
51107204 | Other | AL | BLUE CROSS BLUE SHIELD OF AL |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | DO1144 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr John Kevin Schweninger, DO 34 Hughes Rd, Suite B, Madison, AL 35758-3000 Ph: (256) 319-0115 | Dr John Kevin Schweninger, DO 34 Hughes Rd, Suite B, Madison, AL 35758-3000 Ph: (256) 319-0115 |
News Archive
XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that it has entered into a multi-year agreement with Laboratory Corporation of America Holdings to provide heart transplant patients eligible for XDx's AlloMapĀ® test with the convenience of having their blood drawn at participating LabCorp sites across the United States.
Academics from the University of Birmingham, UK are engaging with grandparents in China, to help tackle the increasing problem of obesity amongst Chinese children in a trailblazing public health programme.
With record-setting snowfall and wet weather in the region this winter, one question comes to mind for many as spring approaches: how bad will my allergies be?
In a comparison of two blood-thinning medications, heparin was associated with significantly fewer major cardiovascular events at 28 days than bivalirudin in patients receiving primary percutaneous coronary intervention after a heart attack, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.
The data are inconclusive on heart risks from a class of blood sugar-lowering drugs called thiazolidinediones (TZDs) such as pioglitazone (Actos) or rosiglitazone (Avandia), but the medications should be used with close monitoring from healthcare providers according to a joint science advisory from the American College of Cardiology and the American Heart Association.
› Verified 3 days ago